Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Authors: Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy, Rong Zhou, Cynthia A. Moylan, Juan P. Frías, Naim Alkhouri, Meena B. Bansal, Seth J. Baum, Brent A. Neuschwander‐Tetri, Rebecca Taub, Sam E. Moussa - The Lancet 2019 cited by 765